Filter Results

Keywords
Active Filters
X Criminalization of Pregnancy and Reproductive Health
X Journal - Report
Active Content Filter
X
Filter by Topic
Jurisdiction

Showing 1 - 15 of 32 results

    • External Resource

    Safety and Efficacy of Telehealth Medication Abortions in the US During the COVID-19 Pandemic by Safety and Efficacy of Telehealth Medication Abortions in the US During the COVID-19 Pandemic by Ushma D. Upadhyay et al. (August 2021)

    Early in the COVID-19 pandemic, medication abortion, which typically includes mifepristone (ie, progesterone receptor antagonist) and misoprostol (ie, prostaglandin), gained prominence because it can be provided without physical contact. The American College of Obstetricians and Gynecologists and other professional organizations quickly endorsed telehealth and no-test abortion care. These protocols omit Rh testing and use patient history, rather than routine ultrasonography, to assess pregnancy duration and screen for ectopic pregnancy risks. To mitigate potential risk of complications, US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) require that mifepristone be dispensed in a medical office, clinic, or hospital, prohibiting dispensing from pharmacies. Between a federal judge’s ruling that suspended enforcement of this requirement in July 2020 and a reversal by the Supreme Court in January 2021, clinicians could offer medication abortion via telehealth and dispense from mail-order pharmacies where not prohibited by state law. During this period, a virtual clinic called Choix began providing medication abortions in California. We assessed safety and efficacy outcomes of a telehealth medication abortion model, which could inform the FDA’s decision regarding removal of the REMS.